45 results on '"Hu, Weiheng"'
Search Results
2. Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis
3. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer
4. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
5. Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism
6. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer
7. The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies
8. The Holographic Studio: Real-time virtual teleportation in Mixed Reality for enhancing design education
9. Real-Time Gaze-Sharing for Enhancing Student-Instructor Communication: Technology-Facilitated Critique in Architectural Design Studios
10. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
11. Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
12. Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
13. Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study.
14. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails
15. Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score- matched cohort study
16. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
17. sj-docx-1-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
18. sj-docx-2-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
19. sj-docx-4-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
20. sj-pdf-3-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
21. Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
22. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
23. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
24. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
25. Salvage treatment with anlotinib for advanced non‐small cell lung cancer
26. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
27. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC
28. Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.
29. Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.
30. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
31. Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer
32. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
33. Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.
34. Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients
35. Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.
36. Circulating PD ‐ L 1 in NSCLC patients and the correlation between the level of PD ‐ L 1 expression and the clinical characteristics
37. Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer
38. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
39. Circulating PD- L1 in NSCLC patients and the correlation between the level of PD- L1 expression and the clinical characteristics.
40. Mesenchymal Stem Cells Modulates Differentiation into Hepatocyte Cell in VX2 Implanted Rabbit Liver Cancer Model.
41. The overall survival benefit in Chinese ALK + NSCLC patients received targeted therapies.
42. [Timing of Brain Radiation Therapy Impacts Outcomes in Patients with Non-small Cell Lung Cancer Who Develop Brain Metastases].
43. [Effects of Local Radiation Combined with Chemotherapy in the treatment of Patients with Extensive-stage Small Cell Lung Cancer].
44. [Multivariate analysis of prognostic factors in the eldly patients with small cell lung cancer: a study of 160 patients].
45. [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.